Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label single-arm study of continuous subcutaneous ABBV-951 in Parkinson's disease
2018-002144-85Phase 3Unknown
- Sponsor
- AbbVie Inc.
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of foscarbidopa in Parkinson's disease (PD), sponsored by AbbVie Inc. Primary endpoint: Safety and tolerability (AEs and SAEs). Status: unknown.
02
Drugs
foscarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2018-002144-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002144-85.